Analysis of Efficacy of Surgical Treatment for IIIa Small Cell Lung Cancer

Small cell lung cancer (SCLC) accounts for nearly 15% of all cases of cancer. As a type of highly invasive tumors, SCLC has high degree of malignancy, early and extensive metastasis, and is sensitive to chemotherapy and radiotherapy. The early treatment response rate of SCLC is high but it can also...

Full description

Saved in:
Bibliographic Details
Published inZhongguo fei ai za zhi Vol. 20; no. 2; pp. 88 - 92
Main Authors Dou, Xuejun, Wang, Zhiyuan, Wang, Liang, Lu, Weiqiang, Ma, Yunlei, Xu, Shaofa
Format Journal Article
LanguageChinese
Published China Chinese Anti-Cancer Association Chinese Antituberculosis Association 20.02.2017
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
Subjects
Adult
Aged
Cancer therapies
Chemotherapy
Comprehensive treatment
Female
Humans
Lung cancer
Lung neoplasms
Lung Neoplasms - diagnosis
Lung Neoplasms - pathology
Lung Neoplasms - surgery
Male
Medical prognosis
Metastasis
Middle Aged
Multivariate analysis
Neoplasm Staging
NMR
Nuclear magnetic resonance
Oncology
Prognosis
Radiation therapy
Retrospective Studies
Small Cell Lung Carcinoma - diagnosis
Small Cell Lung Carcinoma - pathology
Small Cell Lung Carcinoma - surgery
Surgery
Surgical treatment
Thoracic surgery
Treatment Outcome
Tumors
England
Beijing China
California
China
Japan
Online AccessGet full text

Cover

More Information
Summary:Small cell lung cancer (SCLC) accounts for nearly 15% of all cases of cancer. As a type of highly invasive tumors, SCLC has high degree of malignancy, early and extensive metastasis, and is sensitive to chemotherapy and radiotherapy. The early treatment response rate of SCLC is high but it can also relapse rapidly without any treatment. Its median survival time is merely four to six months. Although many studies on SCLC have been conducted in recent years, its clinical treatment strategies have remained unchanged. The treatment of SCLC is still confined to chemotherapy regimens of etoposide plus cisplatin (EP) and other classic treatments because the surgical treatment of SCLC, particularly for IIIa treatment, has yet to reach a consensus. This study investigated the prognostic factors and clinical therapy effect in the comprehensive treatment of IIIa SCLC after surgical treatment. This study was conducted through the retrospective analysis of the clinical data of 78 patients with SCLC who underwent surgical
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1009-3419
1999-6187
DOI:10.3779/j.issn.1009-3419.2017.02.03